#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-3	The	_
1-2	4-11	Effects	_
1-3	12-14	of	_
1-4	15-20	Music	_
1-5	21-33	Intervention	_
1-6	34-36	on	_
1-7	37-49	Pallidum-DMN	_
1-8	50-57	Circuit	_
1-9	58-60	of	_
1-10	61-74	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	75-80	Music	_
1-12	81-93	intervention	_
1-13	94-97	has	_
1-14	98-102	been	_
1-15	103-110	applied	_
1-16	111-113	to	_
1-17	114-121	improve	_
1-18	122-130	symptoms	_
1-19	131-133	of	_
1-20	134-147	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
1-21	148-156	subjects	_
1-22	157-159	as	_
1-23	160-161	a	_
1-24	162-175	complementary	_
1-25	176-185	treatment	_
1-26	186-188	in	_
1-27	189-197	medicine	_
1-28	198-199	.	_

2-1	200-208	Although	_
2-2	209-212	the	_
2-3	213-224	psychiatric	_
2-4	225-233	symptoms	_
2-5	234-235	,	_
2-6	236-246	especially	_
2-7	247-250	for	_
2-8	251-261	motivation	_
2-9	262-265	and	_
2-10	266-273	emotion	_
2-11	274-275	,	_
2-12	276-281	could	_
2-13	282-284	be	_
2-14	285-294	increased	_
2-15	295-297	in	_
2-16	298-311	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-17	312-313	,	_
2-18	314-317	the	_
2-19	318-328	underlying	_
2-20	329-335	neural	_
2-21	336-346	mechanisms	_
2-22	347-353	remain	_
2-23	354-360	poorly	_
2-24	361-371	understood	_
2-25	372-373	.	_

3-1	374-376	We	_
3-2	377-385	employed	_
3-3	386-387	a	_
3-4	388-400	longitudinal	_
3-5	401-406	study	_
3-6	407-409	to	_
3-7	410-417	measure	_
3-8	418-421	the	_
3-9	422-432	alteration	_
3-10	433-435	of	_
3-11	436-444	striatum	_
3-12	445-455	functional	_
3-13	456-464	networks	_
3-14	465-467	in	_
3-15	468-481	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
3-16	482-490	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
3-17	491-501	undergoing	_
3-18	502-508	Mozart	_
3-19	509-514	music	_
3-20	515-524	listening	_
3-21	525-530	using	_
3-22	531-544	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-23	545-555	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-24	556-564	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-25	565-574	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-26	575-582	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-27	583-584	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-28	585-589	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-29	590-591	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-30	592-593	.	_

4-1	594-604	Forty-five	_
4-2	605-618	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-3	619-629	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-4	630-634	were	_
4-5	635-644	recruited	_
4-6	645-648	and	_
4-7	649-657	randomly	_
4-8	658-666	assigned	_
4-9	667-669	to	_
4-10	670-673	two	_
4-11	674-680	groups	_
4-12	681-682	.	_

5-1	683-688	Under	_
5-2	689-692	the	_
5-3	693-701	standard	_
5-4	702-706	care	_
5-5	707-711	with	_
5-6	712-725	antipsychotic	_
5-7	726-736	medication	_
5-8	737-738	,	_
5-9	739-742	one	_
5-10	743-748	group	_
5-11	749-757	received	_
5-12	758-763	music	_
5-13	764-776	intervention	_
5-14	777-780	for	_
5-15	781-782	1	_
5-16	783-788	month	_
5-17	789-792	and	_
5-18	793-796	the	_
5-19	797-802	other	_
5-20	803-808	group	_
5-21	809-811	is	_
5-22	812-815	set	_
5-23	816-818	as	_
5-24	819-826	control	_
5-25	827-828	.	_

6-1	829-833	Both	_
6-2	834-847	schizophrenic	_
6-3	848-854	groups	_
6-4	855-859	were	_
6-5	860-868	compared	_
6-6	869-871	to	_
6-7	872-879	healthy	_
6-8	880-888	subjects	_
6-9	889-890	.	_

7-1	891-904	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
7-2	905-909	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
7-3	910-913	was	_
7-4	914-922	acquired	_
7-5	923-927	from	_
7-6	928-941	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
7-7	942-950	subjects	_
7-8	951-953	at	_
7-9	954-962	baseline	_
7-10	963-966	and	_
7-11	967-972	after	_
7-12	973-982	one-month	_
7-13	983-988	music	_
7-14	989-1001	intervention	_
7-15	1002-1005	and	_
7-16	1006-1010	from	_
7-17	1011-1018	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-18	1019-1027	subjects	_
7-19	1028-1030	at	_
7-20	1031-1039	baseline	_
7-21	1040-1041	.	_

8-1	1042-1050	Striatum	_
8-2	1051-1058	network	_
8-3	1059-1062	was	_
8-4	1063-1071	assessed	_
8-5	1072-1079	through	_
8-6	1080-1090	seed-based	_
8-7	1091-1097	static	_
8-8	1098-1101	and	_
8-9	1102-1109	dynamic	_
8-10	1110-1120	functional	_
8-11	1121-1133	connectivity	_
8-12	1134-1135	(	_
8-13	1136-1138	FC	_
8-14	1139-1140	)	_
8-15	1141-1149	analyses	_
8-16	1150-1151	.	_

9-1	1152-1157	After	_
9-2	1158-1163	music	_
9-3	1164-1176	intervention	_
9-4	1177-1178	,	_
9-5	1179-1188	increased	_
9-6	1189-1195	static	_
9-7	1196-1198	FC	_
9-8	1199-1202	was	_
9-9	1203-1211	observed	_
9-10	1212-1219	between	_
9-11	1220-1228	pallidum	_
9-12	1229-1232	and	_
9-13	1233-1240	ventral	_
9-14	1241-1252	hippocampus	_
9-15	1253-1255	in	_
9-16	1256-1269	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
9-17	1270-1278	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
9-18	1279-1280	.	_

10-1	1281-1290	Increased	_
10-2	1291-1298	dynamic	_
10-3	1299-1302	FCs	_
10-4	1303-1307	were	_
10-5	1308-1312	also	_
10-6	1313-1318	found	_
10-7	1319-1326	between	_
10-8	1327-1335	pallidus	_
10-9	1336-1339	and	_
10-10	1340-1350	subregions	_
10-11	1351-1353	of	_
10-12	1354-1361	default	_
10-13	1362-1366	mode	_
10-14	1367-1374	network	_
10-15	1375-1376	(	_
10-16	1377-1380	DMN	_
10-17	1381-1382	)	_
10-18	1383-1384	,	_
10-19	1385-1394	including	_
10-20	1395-1405	cerebellum	_
10-21	1406-1410	crus	_
10-22	1411-1414	and	_
10-23	1415-1424	posterior	_
10-24	1425-1434	cingulate	_
10-25	1435-1441	cortex	_
10-26	1442-1443	.	_

11-1	1444-1452	Moreover	_
11-2	1453-1454	,	_
11-3	1455-1461	static	_
11-4	1462-1482	pallidus-hippocampus	_
11-5	1483-1485	FC	_
11-6	1486-1495	increment	_
11-7	1496-1499	was	_
11-8	1500-1510	positively	_
11-9	1511-1521	correlated	_
11-10	1522-1526	with	_
11-11	1527-1530	the	_
11-12	1531-1542	improvement	_
11-13	1543-1545	of	_
11-14	1546-1554	negative	_
11-15	1555-1563	symptoms	_
11-16	1564-1566	in	_
11-17	1567-1580	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
11-18	1581-1589	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
11-19	1590-1591	.	_

12-1	1592-1600	Together	_
12-2	1601-1602	,	_
12-3	1603-1608	these	_
12-4	1609-1617	findings	_
12-5	1618-1626	provided	_
12-6	1627-1635	evidence	_
12-7	1636-1640	that	_
12-8	1641-1646	music	_
12-9	1647-1659	intervention	_
12-10	1660-1665	might	_
12-11	1666-1670	have	_
12-12	1671-1673	an	_
12-13	1674-1680	effect	_
12-14	1681-1683	on	_
12-15	1684-1687	the	_
12-16	1688-1690	FC	_
12-17	1691-1693	of	_
12-18	1694-1697	the	_
12-19	1698-1710	striatum-DMN	_
12-20	1711-1718	circuit	_
12-21	1719-1722	and	_
12-22	1723-1728	might	_
12-23	1729-1731	be	_
12-24	1732-1739	related	_
12-25	1740-1742	to	_
12-26	1743-1746	the	_
12-27	1747-1756	remission	_
12-28	1757-1759	of	_
12-29	1760-1768	symptoms	_
12-30	1769-1771	of	_
12-31	1772-1785	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-32	1786-1787	.	_

13-1	1788-1789	2	_
13-2	1790-1791	.	_

14-1	1792-1801	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	1802-1805	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	1806-1813	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	1814-1817	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-5	1818-1819	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

15-1	1820-1831	Demographic	_
15-2	1832-1847	Characteristics	_
15-3	1848-1858	Forty-five	_
15-4	1859-1872	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
15-5	1873-1881	subjects	_
15-6	1882-1886	were	_
15-7	1887-1896	recruited	_
15-8	1897-1899	in	_
15-9	1900-1904	this	_
15-10	1905-1910	study	_
15-11	1911-1915	from	_
15-12	1916-1919	the	_
15-13	1920-1928	clinical	_
15-14	1929-1937	hospital	_
15-15	1938-1940	of	_
15-16	1941-1948	Chengdu	_
15-17	1949-1954	Brain	_
15-18	1955-1962	Science	_
15-19	1963-1972	Institute	_
15-20	1973-1974	(	_
15-21	1975-1979	CBSI	_
15-22	1980-1981	)	_
15-23	1982-1983	.	_

16-1	1984-1987	The	_
16-2	1988-1997	inclusion	_
16-3	1998-2007	criterion	_
16-4	2008-2011	for	_
16-5	2012-2015	the	_
16-6	2016-2026	inpatients	_
16-7	2027-2030	was	_
16-8	2031-2032	a	_
16-9	2033-2042	diagnosis	_
16-10	2043-2045	of	_
16-11	2046-2059	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-12	2060-2065	based	_
16-13	2066-2068	on	_
16-14	2069-2072	the	_
16-15	2073-2083	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-16	2084-2092	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-17	2093-2102	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-18	2103-2106	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-19	2107-2110	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-20	2111-2117	DSM-IV	_
16-21	2118-2122	Axis	_
16-22	2123-2124	I	_
16-23	2125-2143	disorders—clinical	_
16-24	2144-2151	version	_
16-25	2152-2153	(	_
16-26	2154-2163	SCID-I-CV	_
16-27	2164-2165	)	_
16-28	2166-2167	.	_

17-1	2168-2171	The	_
17-2	2172-2181	exclusion	_
17-3	2182-2190	criteria	_
17-4	2191-2195	were	_
17-5	2196-2201	acute	_
17-6	2202-2211	psychotic	_
17-7	2212-2220	symptoms	_
17-8	2221-2222	,	_
17-9	2223-2224	a	_
17-10	2225-2234	secondary	_
17-11	2235-2244	diagnosis	_
17-12	2245-2247	of	_
17-13	2248-2255	organic	_
17-14	2256-2265	psychosis	_
17-15	2266-2268	or	_
17-16	2269-2277	dementia	_
17-17	2278-2279	,	_
17-18	2280-2283	and	_
17-19	2284-2292	unstable	_
17-20	2293-2297	drug	_
17-21	2298-2307	treatment	_
17-22	2308-2309	.	_

18-1	2310-2313	The	_
18-2	2314-2325	psychiatric	_
18-3	2326-2334	symptoms	_
18-4	2335-2337	of	_
18-5	2338-2341	the	_
18-6	2342-2350	patients	_
18-7	2351-2355	were	_
18-8	2356-2364	measured	_
18-9	2365-2370	using	_
18-10	2371-2379	Positive	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-11	2380-2383	and	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-12	2384-2392	Negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-13	2393-2400	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-14	2401-2406	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-15	2407-2408	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-16	2409-2414	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-17	2415-2416	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-18	2417-2418	.	_

19-1	2419-2420	A	_
19-2	2421-2424	set	_
19-3	2425-2427	of	_
19-4	2428-2435	matched	_
19-5	2436-2439	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-6	2440-2444	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-7	2445-2447	of	_
19-8	2448-2455	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-9	2456-2464	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-10	2465-2466	(	_
19-11	2467-2469	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-12	2470-2471	,	_
19-13	2472-2473	n	_
19-14	2474-2475	=	_
19-15	2476-2478	19	_
19-16	2479-2480	)	_
19-17	2481-2485	were	_
19-18	2486-2494	obtained	_
19-19	2495-2499	from	_
19-20	2500-2504	CBSI	_
19-21	2505-2513	research	_
19-22	2514-2523	databases	_
19-23	2524-2525	,	_
19-24	2526-2531	which	_
19-25	2532-2536	were	_
19-26	2537-2545	screened	_
19-27	2546-2549	for	_
19-28	2550-2551	a	_
19-29	2552-2559	history	_
19-30	2560-2562	of	_
19-31	2563-2570	medical	_
19-32	2571-2573	or	_
19-33	2574-2590	neuropsychiatric	_
19-34	2591-2598	illness	_
19-35	2599-2600	,	_
19-36	2601-2603	as	_
19-37	2604-2608	well	_
19-38	2609-2611	as	_
19-39	2612-2615	for	_
19-40	2616-2621	major	_
19-41	2622-2634	neurological	_
19-42	2635-2637	or	_
19-43	2638-2649	psychiatric	_
19-44	2650-2657	illness	_
19-45	2658-2660	in	_
19-46	2661-2666	their	_
19-47	2667-2679	first-degree	_
19-48	2680-2689	relatives	_
19-49	2690-2691	.	_

20-1	2692-2695	The	_
20-2	2696-2701	study	_
20-3	2702-2705	was	_
20-4	2706-2714	approved	_
20-5	2715-2717	by	_
20-6	2718-2721	the	_
20-7	2722-2728	Ethics	_
20-8	2729-2738	Committee	_
20-9	2739-2741	of	_
20-10	2742-2745	the	_
20-11	2746-2754	clinical	_
20-12	2755-2763	hospital	_
20-13	2764-2766	of	_
20-14	2767-2771	CBSI	_
20-15	2772-2774	in	_
20-16	2775-2785	accordance	_
20-17	2786-2790	with	_
20-18	2791-2794	the	_
20-19	2795-2803	Helsinki	_
20-20	2804-2815	Declaration	_
20-21	2816-2817	.	_

21-1	2818-2823	These	_
21-2	2824-2828	data	_
21-3	2829-2833	have	_
21-4	2834-2838	been	_
21-5	2839-2843	used	_
21-6	2844-2846	to	_
21-7	2847-2854	measure	_
21-8	2855-2858	the	_
21-9	2859-2864	music	_
21-10	2865-2877	intervention	_
21-11	2878-2880	on	_
21-12	2881-2887	static	_
21-13	2888-2894	global	_
21-14	2895-2897	FC	_
21-15	2898-2901	and	_
21-16	2902-2909	insular	_
21-17	2910-2918	networks	_
21-18	2919-2920	,	_
21-19	2921-2933	respectively	_
21-20	2934-2935	,	_
21-21	2936-2938	in	_
21-22	2939-2952	schizophrenic	_
21-23	2953-2961	subjects	_
21-24	2962-2963	.	_

22-1	2964-2966	In	_
22-2	2967-2971	this	_
22-3	2972-2977	study	_
22-4	2978-2979	,	_
22-5	2980-2982	we	_
22-6	2983-2990	focused	_
22-7	2991-2993	on	_
22-8	2994-2999	music	_
22-9	3000-3007	effects	_
22-10	3008-3010	on	_
22-11	3011-3017	static	_
22-12	3018-3021	and	_
22-13	3022-3029	dynamic	_
22-14	3030-3032	FC	_
22-15	3033-3035	of	_
22-16	3036-3044	striatum	_
22-17	3045-3047	in	_
22-18	3048-3061	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-19	3062-3063	.	_

23-1	3064-3067	2.2	_
23-2	3068-3069	.	_

24-1	3070-3076	Design	_
24-2	3077-3080	and	_
24-3	3081-3088	Content	_
24-4	3089-3091	of	_
24-5	3092-3097	Music	_
24-6	3098-3110	Intervention	_
24-7	3111-3112	A	_
24-8	3113-3128	quasirandomized	_
24-9	3129-3139	controlled	_
24-10	3140-3145	trial	_
24-11	3146-3149	was	_
24-12	3150-3159	performed	_
24-13	3160-3162	in	_
24-14	3163-3167	this	_
24-15	3168-3173	study	_
24-16	3174-3175	.	_

25-1	3176-3179	The	_
25-2	3180-3192	experimental	_
25-3	3193-3206	schizophrenic	_
25-4	3207-3215	patients	_
25-5	3216-3219	and	_
25-6	3220-3230	controlled	_
25-7	3231-3239	patients	_
25-8	3240-3244	were	_
25-9	3245-3253	compared	_
25-10	3254-3259	using	_
25-11	3260-3263	the	_
25-12	3264-3273	reference	_
25-13	3274-3276	of	_
25-14	3277-3280	the	_
25-15	3281-3284	HCs	_
25-16	3285-3286	.	_

26-1	3287-3291	Then	_
26-2	3292-3293	,	_
26-3	3294-3297	the	_
26-4	3298-3306	patients	_
26-5	3307-3311	were	_
26-6	3312-3320	randomly	_
26-7	3321-3328	divided	_
26-8	3329-3333	into	_
26-9	3334-3337	two	_
26-10	3338-3344	groups	_
26-11	3345-3347	by	_
26-12	3348-3361	psychiatrists	_
26-13	3362-3363	.	_

27-1	3364-3374	Twenty-two	_
27-2	3375-3388	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
27-3	3389-3397	subjects	_
27-4	3398-3402	were	_
27-5	3403-3411	selected	_
27-6	3412-3414	as	_
27-7	3415-3418	the	_
27-8	3419-3424	music	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-9	3425-3437	intervention	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-10	3438-3443	group	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-11	3444-3445	(	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-12	3446-3450	MTSZ	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-13	3451-3452	)	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
27-14	3453-3454	.	_

28-1	3455-3467	Twenty-three	_
28-2	3468-3478	inpatients	_
28-3	3479-3483	were	_
28-4	3484-3490	chosen	_
28-5	3491-3493	as	_
28-6	3494-3502	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-7	3503-3504	(	_
28-8	3505-3510	UMTSZ	_
28-9	3511-3512	)	_
28-10	3513-3514	.	_

29-1	3515-3518	One	_
29-2	3519-3531	professional	_
29-3	3532-3537	music	_
29-4	3538-3547	therapist	_
29-5	3548-3560	participated	_
29-6	3561-3563	in	_
29-7	3564-3568	this	_
29-8	3569-3574	study	_
29-9	3575-3576	.	_

30-1	3577-3580	Two	_
30-2	3581-3587	groups	_
30-3	3588-3590	of	_
30-4	3591-3604	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-5	3605-3608	are	_
30-6	3609-3616	chronic	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
30-7	3617-3630	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
30-8	3631-3639	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
30-9	3640-3644	with	_
30-10	3645-3646	a	_
30-11	3647-3653	stable	_
30-12	3654-3658	drug	_
30-13	3659-3668	treatment	_
30-14	3669-3677	strategy	_
30-15	3678-3679	(	_
30-16	3680-3690	changeless	_
30-17	3691-3704	antipsychotic	_
30-18	3705-3710	drugs	_
30-19	3711-3714	and	_
30-20	3715-3720	their	_
30-21	3721-3726	doses	_
30-22	3727-3728	)	_
30-23	3729-3731	in	_
30-24	3732-3736	CBSI	_
30-25	3737-3738	.	_

31-1	3739-3751	Additionally	_
31-2	3752-3753	,	_
31-3	3754-3758	MTSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-4	3759-3769	inpatients	_
31-5	3770-3778	listened	_
31-6	3779-3785	Mozart	_
31-7	3786-3788	's	_
31-8	3789-3795	sonata	_
31-9	3796-3798	K.	_
31-10	3799-3802	448	_
31-11	3803-3804	(	_
31-12	3805-3809	half	_
31-13	3810-3812	an	_
31-14	3813-3817	hour	_
31-15	3818-3821	per	_
31-16	3822-3825	day	_
31-17	3826-3827	,	_
31-18	3828-3830	30	_
31-19	3831-3835	days	_
31-20	3836-3837	)	_
31-21	3838-3839	,	_
31-22	3840-3845	which	_
31-23	3846-3849	has	_
31-24	3850-3854	been	_
31-25	3855-3861	widely	_
31-26	3862-3866	used	_
31-27	3867-3869	in	_
31-28	3870-3880	scientific	_
31-29	3881-3888	studies	_
31-30	3889-3891	to	_
31-31	3892-3898	assess	_
31-32	3899-3902	the	_
31-33	3903-3910	effects	_
31-34	3911-3913	of	_
31-35	3914-3919	music	_
31-36	3920-3921	.	_

32-1	3922-3928	During	_
32-2	3929-3933	each	_
32-3	3934-3941	session	_
32-4	3942-3943	,	_
32-5	3944-3947	the	_
32-6	3948-3958	inpatients	_
32-7	3959-3963	were	_
32-8	3964-3972	peaceful	_
32-9	3973-3982	listening	_
32-10	3983-3985	to	_
32-11	3986-3989	the	_
32-12	3990-3995	music	_
32-13	3996-3998	of	_
32-14	3999-4005	Mozart	_
32-15	4006-4008	's	_
32-16	4009-4015	sonata	_
32-17	4016-4018	K.	_
32-18	4019-4022	448	_
32-19	4023-4027	from	_
32-20	4028-4029	a	_
32-21	4030-4036	stereo	_
32-22	4037-4043	system	_
32-23	4044-4046	in	_
32-24	4047-4048	a	_
32-25	4049-4054	quiet	_
32-26	4055-4059	room	_
32-27	4060-4061	.	_

33-1	4062-4065	2.3	_
33-2	4066-4067	.	_

34-1	4068-4072	Data	_
34-2	4073-4084	Acquisition	_
34-3	4085-4088	and	_
34-4	4089-4094	Image	_
34-5	4095-4108	Preprocessing	_
34-6	4109-4116	Imaging	_
34-7	4117-4120	was	_
34-8	4121-4130	conducted	_
34-9	4131-4133	on	_
34-10	4134-4135	a	_
34-11	4136-4137	3	_
34-12	4138-4139	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-13	4140-4143	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-14	4144-4151	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-15	4152-4153	(	_
34-16	4154-4156	GE	_
34-17	4157-4166	DISCOVERY	_
34-18	4167-4172	MR750	_
34-19	4173-4174	)	_
34-20	4175-4176	.	_

35-1	4177-4183	During	_
35-2	4184-4192	scanning	_
35-3	4193-4194	,	_
35-4	4195-4197	we	_
35-5	4198-4202	used	_
35-6	4203-4207	foam	_
35-7	4208-4215	padding	_
35-8	4216-4219	and	_
35-9	4220-4228	earplugs	_
35-10	4229-4231	to	_
35-11	4232-4238	reduce	_
35-12	4239-4243	head	_
35-13	4244-4250	motion	_
35-14	4251-4254	and	_
35-15	4255-4262	scanner	_
35-16	4263-4268	noise	_
35-17	4269-4270	,	_
35-18	4271-4283	respectively	_
35-19	4284-4285	.	_

36-1	4286-4301	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
36-2	4302-4313	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-3	4314-4320	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-4	4321-4325	were	_
36-5	4326-4334	acquired	_
36-6	4335-4340	using	_
36-7	4341-4342	a	_
36-8	4343-4356	3-dimensional	_
36-9	4357-4361	fast	_
36-10	4362-4369	spoiled	_
36-11	4370-4383	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
36-12	4384-4392	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
36-13	4393-4394	(	_
36-14	4395-4405	repetition	_
36-15	4406-4410	time	_
36-16	4411-4412	(	_
36-17	4413-4415	TR	_
36-18	4416-4417	)	_
36-19	4418-4419	=	_
36-20	4420-4425	6.008	_
36-21	4426-4428	ms	_
36-22	4429-4430	,	_
36-23	4431-4435	flip	_
36-24	4436-4441	angle	_
36-25	4442-4443	(	_
36-26	4444-4446	FA	_
36-27	4447-4448	)	_
36-28	4449-4450	=	_
36-29	4451-4453	9°	_
36-30	4454-4455	,	_
36-31	4456-4462	matrix	_
36-32	4463-4464	=	_
36-33	4465-4468	256	_
36-34	4469-4470	×	_
36-35	4471-4474	256	_
36-36	4475-4476	,	_
36-37	4477-4482	field	_
36-38	4483-4485	of	_
36-39	4486-4490	view	_
36-40	4491-4492	(	_
36-41	4493-4496	FOV	_
36-42	4497-4498	)	_
36-43	4499-4500	=	_
36-44	4501-4504	256	_
36-45	4505-4506	×	_
36-46	4507-4510	256	_
36-47	4511-4514	mm2	_
36-48	4515-4516	,	_
36-49	4517-4522	slice	_
36-50	4523-4532	thickness	_
36-51	4533-4534	=	_
36-52	4535-4536	1	_
36-53	4537-4539	mm	_
36-54	4540-4541	,	_
36-55	4542-4544	no	_
36-56	4545-4548	gap	_
36-57	4549-4550	,	_
36-58	4551-4554	and	_
36-59	4555-4558	152	_
36-60	4559-4565	slices	_
36-61	4566-4567	)	_
36-62	4568-4569	.	_

37-1	4570-4582	Subsequently	_
37-2	4583-4584	,	_
37-3	4585-4598	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-4	4599-4609	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-5	4610-4613	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-6	4614-4618	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-7	4619-4623	were	_
37-8	4624-4632	acquired	_
37-9	4633-4638	using	_
37-10	4639-4652	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-11	4653-4664	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-12	4665-4672	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-13	4673-4682	sequences	_
37-14	4683-4684	(	_
37-15	4685-4687	TR	_
37-16	4688-4689	=	_
37-17	4690-4694	2000	_
37-18	4695-4697	ms	_
37-19	4698-4699	,	_
37-20	4700-4704	echo	_
37-21	4705-4709	time	_
37-22	4710-4711	(	_
37-23	4712-4714	TE	_
37-24	4715-4716	)	_
37-25	4717-4718	=	_
37-26	4719-4721	30	_
37-27	4722-4724	ms	_
37-28	4725-4726	,	_
37-29	4727-4729	FA	_
37-30	4730-4731	=	_
37-31	4732-4735	90°	_
37-32	4736-4737	,	_
37-33	4738-4744	matrix	_
37-34	4745-4746	=	_
37-35	4747-4749	64	_
37-36	4750-4751	×	_
37-37	4752-4754	64	_
37-38	4755-4756	,	_
37-39	4757-4760	FOV	_
37-40	4761-4762	=	_
37-41	4763-4766	240	_
37-42	4767-4768	×	_
37-43	4769-4772	240	_
37-44	4773-4776	mm2	_
37-45	4777-4778	,	_
37-46	4779-4784	slice	_
37-47	4785-4798	thickness/gap	_
37-48	4799-4800	=	_
37-49	4801-4802	4	_
37-50	4803-4809	mm/0.4	_
37-51	4810-4812	mm	_
37-52	4813-4814	,	_
37-53	4815-4818	and	_
37-54	4819-4825	number	_
37-55	4826-4828	of	_
37-56	4829-4835	slices	_
37-57	4836-4837	=	_
37-58	4838-4840	35	_
37-59	4841-4842	)	_
37-60	4843-4844	,	_
37-61	4845-4849	with	_
37-62	4850-4852	an	_
37-63	4853-4866	eight-channel	_
37-64	4867-4879	phased-array	_
37-65	4880-4884	head	_
37-66	4885-4889	coil	_
37-67	4890-4891	.	_

38-1	4892-4895	All	_
38-2	4896-4904	subjects	_
38-3	4905-4914	underwent	_
38-4	4915-4916	a	_
38-5	4917-4927	510-second	_
38-6	4928-4941	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-7	4942-4946	scan	_
38-8	4947-4949	to	_
38-9	4950-4955	yield	_
38-10	4956-4959	255	_
38-11	4960-4967	volumes	_
38-12	4968-4969	.	_

39-1	4970-4976	During	_
39-2	4977-4990	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-3	4991-4995	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-4	4996-4997	,	_
39-5	4998-5001	all	_
39-6	5002-5010	subjects	_
39-7	5011-5015	were	_
39-8	5016-5026	instructed	_
39-9	5027-5029	to	_
39-10	5030-5034	have	_
39-11	5035-5040	their	_
39-12	5041-5045	eyes	_
39-13	5046-5052	closed	_
39-14	5053-5056	and	_
39-15	5057-5059	to	_
39-16	5060-5064	move	_
39-17	5065-5067	as	_
39-18	5068-5074	little	_
39-19	5075-5077	as	_
39-20	5078-5086	possible	_
39-21	5087-5094	without	_
39-22	5095-5102	falling	_
39-23	5103-5109	asleep	_
39-24	5110-5111	.	_

40-1	5112-5122	Functional	_
40-2	5123-5128	image	_
40-3	5129-5142	preprocessing	_
40-4	5143-5146	was	_
40-5	5147-5156	performed	_
40-6	5157-5162	using	_
40-7	5163-5166	NIT	_
40-8	5167-5168	(	_
40-9	5169-5181	Neuroscience	_
40-10	5182-5193	Information	_
40-11	5194-5201	Toolbox	_
40-12	5202-5203	)	_
40-13	5204-5213	according	_
40-14	5214-5216	to	_
40-15	5217-5218	a	_
40-16	5219-5227	standard	_
40-17	5228-5236	pipeline	_
40-18	5237-5240	and	_
40-19	5241-5248	briefly	_
40-20	5249-5258	described	_
40-21	5259-5263	here	_
40-22	5264-5265	.	_

41-1	5266-5271	Slice	_
41-2	5272-5276	time	_
41-3	5277-5280	and	_
41-4	5281-5285	head	_
41-5	5286-5292	motion	_
41-6	5293-5303	correction	_
41-7	5304-5307	and	_
41-8	5308-5321	normalization	_
41-9	5322-5323	(	_
41-10	5324-5325	3	_
41-11	5326-5328	mm	_
41-12	5329-5330	∗	_
41-13	5331-5332	3	_
41-14	5333-5335	mm	_
41-15	5336-5337	∗	_
41-16	5338-5339	3	_
41-17	5340-5342	mm	_
41-18	5343-5344	)	_
41-19	5345-5349	into	_
41-20	5350-5353	EPI	_
41-21	5354-5362	template	_
41-22	5363-5367	were	_
41-23	5368-5377	performed	_
41-24	5378-5379	.	_

42-1	5380-5387	Further	_
42-2	5388-5389	,	_
42-3	5390-5393	the	_
42-4	5394-5400	images	_
42-5	5401-5405	were	_
42-6	5406-5413	spatial	_
42-7	5414-5422	smoothed	_
42-8	5423-5424	(	_
42-9	5425-5429	FWHM	_
42-10	5430-5431	6	_
42-11	5432-5434	mm	_
42-12	5435-5436	)	_
42-13	5437-5438	.	_

43-1	5439-5449	Detrending	_
43-2	5450-5458	analysis	_
43-3	5459-5462	was	_
43-4	5463-5472	performed	_
43-5	5473-5474	.	_

44-1	5475-5483	Temporal	_
44-2	5484-5493	filtering	_
44-3	5494-5497	was	_
44-4	5498-5507	performed	_
44-5	5508-5510	at	_
44-6	5511-5519	bandpass	_
44-7	5520-5529	0.01–0.08	_
44-8	5530-5532	Hz	_
44-9	5533-5534	.	_

45-1	5535-5539	Then	_
45-2	5540-5541	,	_
45-3	5542-5545	the	_
45-4	5546-5553	sources	_
45-5	5554-5556	of	_
45-6	5557-5565	nuisance	_
45-7	5566-5573	signals	_
45-8	5574-5578	were	_
45-9	5579-5586	removed	_
45-10	5587-5591	from	_
45-11	5592-5597	these	_
45-12	5598-5604	images	_
45-13	5605-5606	,	_
45-14	5607-5616	including	_
45-15	5617-5620	six	_
45-16	5621-5627	motion	_
45-17	5628-5638	parameters	_
45-18	5639-5642	and	_
45-19	5643-5648	their	_
45-20	5649-5654	first	_
45-21	5655-5663	temporal	_
45-22	5664-5674	derivative	_
45-23	5675-5676	,	_
45-24	5677-5682	white	_
45-25	5683-5689	matter	_
45-26	5690-5696	signal	_
45-27	5697-5698	,	_
45-28	5699-5702	and	_
45-29	5703-5716	cerebrospinal	_
45-30	5717-5722	fluid	_
45-31	5723-5729	signal	_
45-32	5730-5731	.	_

46-1	5732-5735	The	_
46-2	5736-5742	global	_
46-3	5743-5749	signal	_
46-4	5750-5753	was	_
46-5	5754-5757	not	_
46-6	5758-5767	regressed	_
46-7	5768-5771	out	_
46-8	5772-5773	.	_

47-1	5774-5779	Power	_
47-2	5780-5788	reported	_
47-3	5789-5793	that	_
47-4	5794-5798	head	_
47-5	5799-5805	motion	_
47-6	5806-5809	has	_
47-7	5810-5811	a	_
47-8	5812-5823	substantial	_
47-9	5824-5830	impact	_
47-10	5831-5833	on	_
47-11	5834-5837	the	_
47-12	5838-5848	functional	_
47-13	5849-5852	map	_
47-14	5853-5854	.	_

48-1	5855-5859	Thus	_
48-2	5860-5861	,	_
48-3	5862-5864	in	_
48-4	5865-5869	this	_
48-5	5870-5875	study	_
48-6	5876-5877	,	_
48-7	5878-5886	subjects	_
48-8	5887-5890	who	_
48-9	5891-5894	had	_
48-10	5895-5896	a	_
48-11	5897-5904	maximum	_
48-12	5905-5916	translation	_
48-13	5917-5919	in	_
48-14	5920-5923	any	_
48-15	5924-5926	of	_
48-16	5927-5937	orthogonal	_
48-17	5938-5947	direction	_
48-18	5948-5954	larger	_
48-19	5955-5959	than	_
48-20	5960-5961	3	_
48-21	5962-5964	mm	_
48-22	5965-5967	or	_
48-23	5968-5976	rotation	_
48-24	5977-5983	larger	_
48-25	5984-5988	than	_
48-26	5989-5990	3	_
48-27	5991-5998	degrees	_
48-28	5999-6003	were	_
48-29	6004-6012	excluded	_
48-30	6013-6014	.	_

49-1	6015-6023	Moreover	_
49-2	6024-6025	,	_
49-3	6026-6035	framewise	_
49-4	6036-6048	displacement	_
49-5	6049-6050	(	_
49-6	6051-6053	FD	_
49-7	6054-6055	)	_
49-8	6056-6059	was	_
49-9	6060-6069	evaluated	_
49-10	6070-6073	for	_
49-11	6074-6077	all	_
49-12	6078-6086	subjects	_
49-13	6087-6089	as	_
49-14	6090-6099	suggested	_
49-15	6100-6102	by	_
49-16	6103-6108	Power	_
49-17	6109-6111	et	_
49-18	6112-6114	al	_
49-19	6115-6116	.	_

50-1	6117-6127	Structural	_
50-2	6128-6134	images	_
50-3	6135-6139	were	_
50-4	6140-6149	processed	_
50-5	6150-6155	using	_
50-6	6156-6160	SPM8	_
50-7	6161-6168	toolbox	_
50-8	6169-6170	.	_

51-1	6171-6174	The	_
51-2	6175-6185	structural	_
51-3	6186-6191	image	_
51-4	6192-6195	was	_
51-5	6196-6205	spatially	_
51-6	6206-6216	normalized	_
51-7	6217-6219	to	_
51-8	6220-6223	MNI	_
51-9	6224-6229	space	_
51-10	6230-6235	using	_
51-11	6236-6237	a	_
51-12	6238-6251	diffeomorphic	_
51-13	6252-6262	anatomical	_
51-14	6263-6275	registration	_
51-15	6276-6283	through	_
51-16	6284-6297	exponentiated	_
51-17	6298-6301	lie	_
51-18	6302-6309	algebra	_
51-19	6310-6311	(	_
51-20	6312-6318	DARTEL	_
51-21	6319-6320	)	_
51-22	6321-6324	and	_
51-23	6325-6334	segmented	_
51-24	6335-6339	into	_
51-25	6340-6344	gray	_
51-26	6345-6351	matter	_
51-27	6352-6353	(	_
51-28	6354-6356	GM	_
51-29	6357-6358	)	_
51-30	6359-6360	,	_
51-31	6361-6366	white	_
51-32	6367-6373	matter	_
51-33	6374-6375	,	_
51-34	6376-6379	and	_
51-35	6380-6393	cerebrospinal	_
51-36	6394-6399	fluid	_
51-37	6400-6401	.	_

52-1	6402-6406	Then	_
52-2	6407-6410	the	_
52-3	6411-6420	segmented	_
52-4	6421-6423	GM	_
52-5	6424-6427	was	_
52-6	6428-6437	modulated	_
52-7	6438-6443	using	_
52-8	6444-6453	nonlinear	_
52-9	6454-6465	deformation	_
52-10	6466-6467	.	_

53-1	6468-6471	The	_
53-2	6472-6482	normalized	_
53-3	6483-6485	GM	_
53-4	6486-6491	score	_
53-5	6492-6495	was	_
53-6	6496-6506	calculated	_
53-7	6507-6509	as	_
53-8	6510-6517	follows	_
53-9	6518-6519	:	_
53-10	6520-6522	GM	_
53-11	6523-6528	score	_
53-12	6529-6536	divided	_
53-13	6537-6539	by	_
53-14	6540-6543	the	_
53-15	6544-6549	total	_
53-16	6550-6562	intracranial	_
53-17	6563-6569	volume	_
53-18	6570-6571	.	_

54-1	6572-6575	The	_
54-2	6576-6586	normalized	_
54-3	6587-6589	GM	_
54-4	6590-6595	score	_
54-5	6596-6598	of	_
54-6	6599-6607	subjects	_
54-7	6608-6611	was	_
54-8	6612-6614	as	_
54-9	6615-6616	a	_
54-10	6617-6625	variable	_
54-11	6626-6628	in	_
54-12	6629-6632	the	_
54-13	6633-6644	statistical	_
54-14	6645-6653	analysis	_
54-15	6654-6656	to	_
54-16	6657-6664	correct	_
54-17	6665-6668	for	_
54-18	6669-6672	the	_
54-19	6673-6679	global	_
54-20	6680-6682	GM	_
54-21	6683-6689	volume	_
54-22	6690-6692	of	_
54-23	6693-6702	different	_
54-24	6703-6711	subjects	_
54-25	6712-6713	.	_

55-1	6714-6717	2.4	_
55-2	6718-6719	.	_

56-1	6720-6726	Static	_
56-2	6727-6730	and	_
56-3	6731-6738	Sliding	_
56-4	6739-6751	Window-Based	_
56-5	6752-6759	Dynamic	_
56-6	6760-6770	Functional	_
56-7	6771-6783	Connectivity	_
56-8	6784-6792	Analyses	_
56-9	6793-6798	First	_
56-10	6799-6800	,	_
56-11	6801-6803	we	_
56-12	6804-6814	calculated	_
56-13	6815-6821	static	_
56-14	6822-6832	functional	_
56-15	6833-6841	networks	_
56-16	6842-6844	of	_
56-17	6845-6848	the	_
56-18	6849-6857	striatum	_
56-19	6858-6864	system	_
56-20	6865-6866	.	_

57-1	6867-6870	Six	_
57-2	6871-6881	subregions	_
57-3	6882-6888	within	_
57-4	6889-6897	striatum	_
57-5	6898-6905	systems	_
57-6	6906-6910	were	_
57-7	6911-6918	defined	_
57-8	6919-6924	based	_
57-9	6925-6927	on	_
57-10	6928-6931	the	_
57-11	6932-6941	automated	_
57-12	6942-6952	anatomical	_
57-13	6953-6961	labeling	_
57-14	6962-6963	(	_
57-15	6964-6967	AAL	_
57-16	6968-6969	)	_
57-17	6970-6978	template	_
57-18	6979-6980	,	_
57-19	6981-6990	including	_
57-20	6991-6995	left	_
57-21	6996-6999	and	_
57-22	7000-7005	right	_
57-23	7006-7013	caudate	_
57-24	7014-7015	,	_
57-25	7016-7020	left	_
57-26	7021-7024	and	_
57-27	7025-7030	right	_
57-28	7031-7038	putamen	_
57-29	7039-7040	,	_
57-30	7041-7044	and	_
57-31	7045-7049	left	_
57-32	7050-7053	and	_
57-33	7054-7059	right	_
57-34	7060-7068	pallidum	_
57-35	7069-7070	.	_

58-1	7071-7074	The	_
58-2	7075-7079	mean	_
58-3	7080-7084	BOLD	_
58-4	7085-7089	time	_
58-5	7090-7097	courses	_
58-6	7098-7100	of	_
58-7	7101-7106	these	_
58-8	7107-7114	regions	_
58-9	7115-7119	were	_
58-10	7120-7129	extracted	_
58-11	7130-7131	.	_

59-1	7132-7144	Subsequently	_
59-2	7145-7146	,	_
59-3	7147-7150	the	_
59-4	7151-7158	Pearson	_
59-5	7159-7170	correlation	_
59-6	7171-7183	coefficients	_
59-7	7184-7188	were	_
59-8	7189-7199	calculated	_
59-9	7200-7207	between	_
59-10	7208-7213	these	_
59-11	7214-7221	regions	_
59-12	7222-7225	and	_
59-13	7226-7229	all	_
59-14	7230-7236	voxels	_
59-15	7237-7239	in	_
59-16	7240-7243	the	_
59-17	7244-7249	brain	_
59-18	7250-7251	.	_

60-1	7252-7256	This	_
60-2	7257-7268	correlation	_
60-3	7269-7280	coefficient	_
60-4	7281-7284	was	_
60-5	7285-7295	considered	_
60-6	7296-7298	as	_
60-7	7299-7305	static	_
60-8	7306-7308	FC	_
60-9	7309-7314	based	_
60-10	7315-7317	on	_
60-11	7318-7321	the	_
60-12	7322-7327	whole	_
60-13	7328-7332	time	_
60-14	7333-7339	course	_
60-15	7340-7341	.	_

61-1	7342-7345	The	_
61-2	7346-7355	resulting	_
61-3	7356-7362	values	_
61-4	7363-7367	were	_
61-5	7368-7379	transformed	_
61-6	7380-7387	through	_
61-7	7388-7394	Fisher	_
61-8	7395-7397	's	_
61-9	7398-7404	r-to-z	_
61-10	7405-7419	transformation	_
61-11	7420-7421	.	_

62-1	7422-7424	We	_
62-2	7425-7435	calculated	_
62-3	7436-7439	the	_
62-4	7440-7447	sliding	_
62-5	7448-7460	window-based	_
62-6	7461-7468	dynamic	_
62-7	7469-7479	functional	_
62-8	7480-7483	map	_
62-9	7484-7487	for	_
62-10	7488-7492	each	_
62-11	7493-7502	subregion	_
62-12	7503-7505	of	_
62-13	7506-7509	the	_
62-14	7510-7518	striatum	_
62-15	7519-7525	system	_
62-16	7526-7528	as	_
62-17	7529-7536	follows	_
62-18	7537-7538	:	_
62-19	7539-7544	first	_
62-20	7545-7546	,	_
62-21	7547-7550	the	_
62-22	7551-7555	time	_
62-23	7556-7562	course	_
62-24	7563-7566	was	_
62-25	7567-7576	segmented	_
62-26	7577-7581	into	_
62-27	7582-7589	shorter	_
62-28	7590-7597	windows	_
62-29	7598-7599	.	_

63-1	7600-7602	In	_
63-2	7603-7606	the	_
63-3	7607-7614	sliding	_
63-4	7615-7627	window-based	_
63-5	7628-7635	dynamic	_
63-6	7636-7646	functional	_
63-7	7647-7659	connectivity	_
63-8	7660-7668	analysis	_
63-9	7669-7670	,	_
63-10	7671-7674	the	_
63-11	7675-7682	optimal	_
63-12	7683-7689	window	_
63-13	7690-7696	length	_
63-14	7697-7699	is	_
63-15	7700-7702	an	_
63-16	7703-7707	open	_
63-17	7708-7712	area	_
63-18	7713-7715	of	_
63-19	7716-7724	research	_
63-20	7725-7726	.	_

64-1	7727-7733	Recent	_
64-2	7734-7739	study	_
64-3	7740-7743	has	_
64-4	7744-7753	indicated	_
64-5	7754-7758	that	_
64-6	7759-7762	the	_
64-7	7763-7770	minimum	_
64-8	7771-7777	window	_
64-9	7778-7784	length	_
64-10	7785-7791	should	_
64-11	7792-7794	be	_
64-12	7795-7797	no	_
64-13	7798-7802	less	_
64-14	7803-7807	than	_
64-15	7808-7814	1/fmin	_
64-16	7815-7816	.	_

65-1	7817-7821	Thus	_
65-2	7822-7823	,	_
65-3	7824-7827	the	_
65-4	7828-7832	time	_
65-5	7833-7840	courses	_
65-6	7841-7845	were	_
65-7	7846-7855	segmented	_
65-8	7856-7860	into	_
65-9	7861-7864	100	_
65-10	7865-7866	s	_
65-11	7867-7868	(	_
65-12	7869-7873	50TR	_
65-13	7874-7875	)	_
65-14	7876-7883	windows	_
65-15	7884-7885	(	_
65-16	7886-7890	fmin	_
65-17	7891-7892	=	_
65-18	7893-7897	0.01	_
65-19	7898-7900	Hz	_
65-20	7901-7902	)	_
65-21	7903-7904	,	_
65-22	7905-7912	sliding	_
65-23	7913-7916	the	_
65-24	7917-7922	onset	_
65-25	7923-7925	by	_
65-26	7926-7927	2	_
65-27	7928-7929	s	_
65-28	7930-7931	(	_
65-29	7932-7935	1TR	_
65-30	7936-7937	)	_
65-31	7938-7939	.	_

66-1	7940-7946	Second	_
66-2	7947-7948	,	_
66-3	7949-7955	within	_
66-4	7956-7960	each	_
66-5	7961-7967	window	_
66-6	7968-7969	,	_
66-7	7970-7973	the	_
66-8	7974-7981	Pearson	_
66-9	7982-7993	correlation	_
66-10	7994-8002	analysis	_
66-11	8003-8006	was	_
66-12	8007-8016	performed	_
66-13	8017-8024	between	_
66-14	8025-8028	the	_
66-15	8029-8039	subregions	_
66-16	8040-8042	of	_
66-17	8043-8051	striatum	_
66-18	8052-8055	and	_
66-19	8056-8059	all	_
66-20	8060-8066	voxels	_
66-21	8067-8068	,	_
66-22	8069-8081	respectively	_
66-23	8082-8083	.	_

67-1	8084-8091	Finally	_
67-2	8092-8093	,	_
67-3	8094-8097	the	_
67-4	8098-8105	dynamic	_
67-5	8106-8108	FC	_
67-6	8109-8112	was	_
67-7	8113-8122	estimated	_
67-8	8123-8125	by	_
67-9	8126-8137	calculating	_
67-10	8138-8141	the	_
67-11	8142-8150	standard	_
67-12	8151-8160	deviation	_
67-13	8161-8162	(	_
67-14	8163-8165	SD	_
67-15	8166-8167	)	_
67-16	8168-8170	in	_
67-17	8171-8182	correlation	_
67-18	8183-8195	coefficients	_
67-19	8196-8198	at	_
67-20	8199-8203	each	_
67-21	8204-8209	voxel	_
67-22	8210-8211	.	_

68-1	8212-8215	2.5	_
68-2	8216-8217	.	_

69-1	8218-8229	Statistical	_
69-2	8230-8238	Analysis	_
69-3	8239-8244	First	_
69-4	8245-8246	,	_
69-5	8247-8249	to	_
69-6	8250-8257	measure	_
69-7	8258-8261	the	_
69-8	8262-8269	effects	_
69-9	8270-8272	of	_
69-10	8273-8278	music	_
69-11	8279-8291	intervention	_
69-12	8292-8294	on	_
69-13	8295-8301	static	_
69-14	8302-8305	and	_
69-15	8306-8313	dynamic	_
69-16	8314-8324	functional	_
69-17	8325-8333	networks	_
69-18	8334-8335	,	_
69-19	8336-8339	the	_
69-20	8340-8351	statistical	_
69-21	8352-8360	analysis	_
69-22	8361-8364	was	_
69-23	8365-8374	performed	_
69-24	8375-8377	on	_
69-25	8378-8381	the	_
69-26	8382-8394	longitudinal	_
69-27	8395-8399	date	_
69-28	8400-8402	of	_
69-29	8403-8407	MTSZ	_
69-30	8408-8411	and	_
69-31	8412-8417	UMTSZ	_
69-32	8418-8424	groups	_
69-33	8425-8432	through	_
69-34	8433-8449	repeated-measure	_
69-35	8450-8455	ANOVA	_
69-36	8456-8457	.	_

70-1	8458-8461	The	_
70-2	8462-8478	repeated-measure	_
70-3	8479-8484	ANOVA	_
70-4	8485-8488	was	_
70-5	8489-8498	performed	_
70-6	8499-8503	with	_
70-7	8504-8507	age	_
70-8	8508-8509	,	_
70-9	8510-8516	gender	_
70-10	8517-8518	,	_
70-11	8519-8528	education	_
70-12	8529-8534	years	_
70-13	8535-8536	,	_
70-14	8537-8539	GM	_
70-15	8540-8541	,	_
70-16	8542-8545	and	_
70-17	8546-8556	medication	_
70-18	8557-8563	dosage	_
70-19	8564-8566	as	_
70-20	8567-8577	covariates	_
70-21	8578-8579	.	_

71-1	8580-8588	Multiple	_
71-2	8589-8600	comparisons	_
71-3	8601-8611	correction	_
71-4	8612-8615	was	_
71-5	8616-8625	performed	_
71-6	8626-8631	using	_
71-7	8632-8633	a	_
71-8	8634-8638	high	_
71-9	8639-8648	threshold	_
71-10	8649-8650	(	_
71-11	8651-8658	p=0.001	_
71-12	8659-8660	)	_
71-13	8661-8664	and	_
71-14	8665-8667	an	_
71-15	8668-8674	extent	_
71-16	8675-8684	threshold	_
71-17	8685-8690	based	_
71-18	8691-8693	on	_
71-19	8694-8702	Gaussian	_
71-20	8703-8709	random	_
71-21	8710-8715	field	_
71-22	8716-8722	theory	_
71-23	8723-8724	(	_
71-24	8725-8740	pcorrected=0.05	_
71-25	8741-8742	)	_
71-26	8743-8744	.	_

72-1	8745-8748	For	_
72-2	8749-8752	the	_
72-3	8753-8760	altered	_
72-4	8761-8768	regions	_
72-5	8769-8770	,	_
72-6	8771-8773	we	_
72-7	8774-8783	extracted	_
72-8	8784-8787	the	_
72-9	8788-8790	FC	_
72-10	8791-8796	value	_
72-11	8797-8799	in	_
72-12	8800-8804	MTSZ	_
72-13	8805-8808	and	_
72-14	8809-8814	UMTSZ	_
72-15	8815-8821	groups	_
72-16	8822-8825	for	_
72-17	8826-8830	post	_
72-18	8831-8834	hoc	_
72-19	8835-8843	analysis	_
72-20	8844-8845	.	_

73-1	8846-8852	Second	_
73-2	8853-8854	,	_
73-3	8855-8858	for	_
73-4	8859-8862	the	_
73-5	8863-8870	altered	_
73-6	8871-8873	FC	_
73-7	8874-8878	from	_
73-8	8879-8895	repeated-measure	_
73-9	8896-8901	ANOVA	_
73-10	8902-8903	,	_
73-11	8904-8906	we	_
73-12	8907-8918	established	_
73-13	8919-8922	the	_
73-14	8923-8931	baseline	_
73-15	8932-8945	abnormalities	_
73-16	8946-8953	between	_
73-17	8954-8956	HC	_
73-18	8957-8960	and	_
73-19	8961-8965	MTSZ	_
73-20	8966-8967	,	_
73-21	8968-8971	and	_
73-22	8972-8977	UMTSZ	_
73-23	8978-8979	,	_
73-24	8980-8992	respectively	_
73-25	8993-8994	.	_

74-1	8995-9005	Two-sample	_
74-2	9006-9012	t-test	_
74-3	9013-9016	was	_
74-4	9017-9027	calculated	_
74-5	9028-9035	between	_
74-6	9036-9038	HC	_
74-7	9039-9042	and	_
74-8	9043-9056	schizophrenic	_
74-9	9057-9065	subjects	_
74-10	9066-9067	(	_
74-11	9068-9072	MTSZ	_
74-12	9073-9076	and	_
74-13	9077-9082	UMTSZ	_
74-14	9083-9085	of	_
74-15	9086-9094	baseline	_
74-16	9095-9096	)	_
74-17	9097-9098	.	_

75-1	9099-9104	Using	_
75-2	9105-9108	the	_
75-3	9109-9118	different	_
75-4	9119-9121	FC	_
75-5	9122-9129	between	_
75-6	9130-9132	HC	_
75-7	9133-9136	and	_
75-8	9137-9145	patients	_
75-9	9146-9148	as	_
75-10	9149-9150	a	_
75-11	9151-9160	reference	_
75-12	9161-9162	,	_
75-13	9163-9166	the	_
75-14	9167-9174	inverse	_
75-15	9175-9177	FC	_
75-16	9178-9179	(	_
75-17	9180-9181	1	_
75-18	9182-9187	month	_
75-19	9188-9193	minus	_
75-20	9194-9202	baseline	_
75-21	9203-9204	)	_
75-22	9205-9210	might	_
75-23	9211-9213	be	_
75-24	9214-9221	defined	_
75-25	9222-9224	as	_
75-26	9225-9235	normalized	_
75-27	9236-9238	FC	_
75-28	9239-9246	through	_
75-29	9247-9252	music	_
75-30	9253-9265	intervention	_
75-31	9266-9268	in	_
75-32	9269-9273	MTSZ	_
75-33	9274-9275	.	_

76-1	9276-9279	2.6	_
76-2	9280-9281	.	_

77-1	9282-9294	Correlations	_
77-2	9295-9299	with	_
77-3	9300-9312	Pathological	_
77-4	9313-9320	Factors	_
77-5	9321-9324	The	_
77-6	9325-9332	partial	_
77-7	9333-9344	correlation	_
77-8	9345-9353	analysis	_
77-9	9354-9357	was	_
77-10	9358-9367	performed	_
77-11	9368-9375	between	_
77-12	9376-9379	the	_
77-13	9380-9384	mean	_
77-14	9385-9392	changed	_
77-15	9393-9407	static/dynamic	_
77-16	9408-9410	FC	_
77-17	9411-9412	(	_
77-18	9413-9414	1	_
77-19	9415-9420	month	_
77-20	9421-9426	later	_
77-21	9427-9432	minus	_
77-22	9433-9441	baseline	_
77-23	9442-9443	)	_
77-24	9444-9448	with	_
77-25	9449-9456	altered	_
77-26	9457-9464	symptom	_
77-27	9465-9471	scores	_
77-28	9472-9473	(	_
77-29	9474-9475	1	_
77-30	9476-9481	month	_
77-31	9482-9487	later	_
77-32	9488-9493	minus	_
77-33	9494-9502	baseline	_
77-34	9503-9504	)	_
77-35	9505-9507	of	_
77-36	9508-9521	schizophrenic	_
77-37	9522-9530	subjects	_
77-38	9531-9535	with	_
77-39	9536-9539	age	_
77-40	9540-9541	,	_
77-41	9542-9548	gender	_
77-42	9549-9550	,	_
77-43	9551-9558	illness	_
77-44	9559-9567	duration	_
77-45	9568-9569	,	_
77-46	9570-9579	education	_
77-47	9580-9585	years	_
77-48	9586-9587	,	_
77-49	9588-9590	GM	_
77-50	9591-9592	,	_
77-51	9593-9596	and	_
77-52	9597-9607	medication	_
77-53	9608-9614	dosage	_
77-54	9615-9617	as	_
77-55	9618-9628	covariates	_
77-56	9629-9631	in	_
77-57	9632-9636	this	_
77-58	9637-9642	study	_
77-59	9643-9644	.	_

